FDA's morale spending irks Congress

The US Food and Drug Administration is raising hackles on Capitol Hill where lawmakers are peeved that the agency has paid a consultant more than one million dollars to raise the spirits of FDA employees. Morale at the FDA seems to have hit an all time low, with internal and public voices levying criticisms against the agency for approving high-profile drugs that turned out to be unsafe. (See our December 2008 feature on morale problems at the FDA). The linkurl:__Wall Street Journal__;http://o

Written byBob Grant
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
The US Food and Drug Administration is raising hackles on Capitol Hill where lawmakers are peeved that the agency has paid a consultant more than one million dollars to raise the spirits of FDA employees. Morale at the FDA seems to have hit an all time low, with internal and public voices levying criticisms against the agency for approving high-profile drugs that turned out to be unsafe. (See our December 2008 feature on morale problems at the FDA). The linkurl:__Wall Street Journal__;http://online.wsj.com/article/SB123137470811862863.html?mod=googlenews_wsj reports today that in 2007 the FDA paid approximately $1.5 million to Oakland, CA-based consultant firm Center for Professional Development Inc. FDA employees, attending a recent retreat, were shown a slideshow prepared by the company that likened Janet Woodcock, head of the agency's Center for Drug Evaluation, to Golda Meir, Steve Jobs, and Mahatma Gandhi, among others. Several lawmakers weighed in on the hiring of the consultant and the slideshow, as House Republicans on the Energy and Commerce Committee opened an inquiry into the contract. "It's a cinch that if I spent a nickel of taxpayers' money to rank myself with [Sam] Houston and [Stephen F.] Austin, I'd have some explaining to do after the laughter died down," Republican Congressman from Texas Joe Barton told the __Wall Street Journal__. Rep. John Shimkus (R., Ill.) told the __Wall Street Journal__ that the retreat was a waste of time. "To remove managers for two days to discuss this morale problem, instead of putting food and drug safety first, is ridiculous," he said.
**__Related stories:__***linkurl:Morale Mire;http://www.the-scientist.com/article/display/55234/
[December 2008]*linkurl:House berates FDA, drug makers;http://www.the-scientist.com/article/display/22398/
[10 September 2004]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies